| Molecular Weight: | 383.2 |
| Volume: | 393.025 |
| LogP: | 3.466 |
| LogD: | 3.303 |
| LogS: | -4.37 |
| # Rotatable Bonds: | 6 |
| TPSA: | 44.81 |
| # H-Bond Aceptor: | 5 |
| # H-Bond Donor: | 1 |
| # Rings: | 4 |
| # Heavy Atoms: | 6 |
| QED Drug-Likeness Score: | 0.779 |
| Synthetic Accessibility Score: | 2.734 |
| Fsp3: | 0.409 |
| Lipinski Rule-of-5: | Accepted |
| Pfizer Rule: | Rejected |
| GSK Rule: | Accepted |
| BMS Rule: | 0 |
| Golden Triangle Rule: | Accepted |
| Chelating Alert: | 0 |
| PAINS Alert: | 0 |
| Caco-2 Permeability: | -4.86 |
| MDCK Permeability: | 1.94E-05 |
| Pgp-inhibitor: | 0.991 |
| Pgp-substrate: | 0.028 |
| Human Intestinal Absorption (HIA): | 0.01 |
| 20% Bioavailability (F20%): | 0.003 |
| 30% Bioavailability (F30%): | 0.01 |
| Blood-Brain-Barrier Penetration (BBB): | 0.991 |
| Plasma Protein Binding (PPB): | 91.72% |
| Volume Distribution (VD): | 2.808 |
| Pgp-substrate: | 7.88% |
| CYP1A2-inhibitor: | 0.075 |
| CYP1A2-substrate: | 0.36 |
| CYP2C19-inhibitor: | 0.43 |
| CYP2C19-substrate: | 0.883 |
| CYP2C9-inhibitor: | 0.046 |
| CYP2C9-substrate: | 0.062 |
| CYP2D6-inhibitor: | 0.984 |
| CYP2D6-substrate: | 0.907 |
| CYP3A4-inhibitor: | 0.02 |
| CYP3A4-substrate: | 0.214 |
| Clearance (CL): | 8.413 |
| Half-life (T1/2): | 0.048 |
| hERG Blockers: | 0.74 |
| Human Hepatotoxicity (H-HT): | 0.944 |
| Drug-inuced Liver Injury (DILI): | 0.079 |
| AMES Toxicity: | 0.437 |
| Rat Oral Acute Toxicity: | 0.874 |
| Maximum Recommended Daily Dose: | 0.826 |
| Skin Sensitization: | 0.335 |
| Carcinogencity: | 0.797 |
| Eye Corrosion: | 0.003 |
| Eye Irritation: | 0.011 |
| Respiratory Toxicity: | 0.968 |
Natural Product: NPC315257| Natural Product ID: | NPC315257 |
| Common Name*: | Spiramide |
| IUPAC Name: | 8-[3-(4-fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one |
| Synonyms: | Fluroxyspiramine; R-5808; Spiramide |
| Standard InCHIKey: | FJUKDAZEABGEIH-UHFFFAOYSA-N |
| Standard InCHI: | InChI=1S/C22H26FN3O2/c23-18-7-9-20(10-8-18)28-16-4-13-25-14-11-22(12-15-25)21(27)24-17-26(22)19-5-2-1-3-6-19/h1-3,5-10H,4,11-17H2,(H,24,27) |
| SMILES: | Fc1ccc(cc1)OCCCN1CCC2(CC1)C(=NCN2c1ccccc1)O |
| Synthetic Gene Cluster: | n.a. |
| ChEMBL Identifier: | CHEMBL79834 |
| PubChem CID: |
68186 |
| Chemical Classification**: |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Species Source| Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
|---|---|---|---|---|---|---|---|---|
| NPO6485.1 | Spiraea japonica var. acuta | Varieties | Rosaceae | Eukaryota | n.a. | n.a. | n.a. | Database[HerDing] |
| NPO6485.1 | Spiraea japonica var. acuta | Varieties | Rosaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
NP Quantity Composition/Concentration| Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
|---|
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Biological Activity| Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
|---|---|---|---|---|---|---|---|---|
| NPT288 | Individual Protein | Serotonin 1a (5-HT1a) receptor | Rattus norvegicus | Ki | = | 50.0 | nM | PMID[467934] |
| NPT438 | Individual Protein | Serotonin 2c (5-HT2c) receptor | Rattus norvegicus | Ki | = | 4300.0 | nM | PMID[467934] |
| NPT5857 | Individual Protein | Dopamine D1 receptor | Mus musculus | Ki | = | 2530.0 | nM | PMID[467934] |
| NPT243 | Individual Protein | Dopamine D2 receptor | Homo sapiens | Ki | = | 3.0 | nM | PMID[467934] |
| NPT290 | Individual Protein | Serotonin 2a (5-HT2a) receptor | Homo sapiens | IC50 | = | 0.3162 | nM | PMID[467935] |
| NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 5011.9 | nM | PMID[467936] |
| NPT150 | Individual Protein | Anthrax lethal factor | Bacillus anthracis | Potency | = | 7943.3 | nM | PMID[467936] |
| NPT110 | Individual Protein | Cytochrome P450 2D6 | Homo sapiens | Potency | = | 158.5 | nM | PMID[467936] |
| NPT1139 | Individual Protein | Arachidonate 15-lipoxygenase, type II | Homo sapiens | Potency | n.a. | 5011.9 | nM | PMID[467936] |
| NPT208 | Individual Protein | Cytochrome P450 1A2 | Homo sapiens | AC50 | = | 39810.72 | nM | PMID[467936] |
| NPT110 | Individual Protein | Cytochrome P450 2D6 | Homo sapiens | AC50 | = | 158.49 | nM | PMID[467936] |
| NPT444 | Individual Protein | Ubiquitin carboxyl-terminal hydrolase 1 | Homo sapiens | Potency | n.a. | 56234.1 | nM | PMID[467936] |
| NPT445 | Individual Protein | Peripheral myelin protein 22 | Rattus norvegicus | Potency | n.a. | 22793.6 | nM | PMID[467938] |
| NPT10 | Individual Protein | Geminin | Homo sapiens | Potency | n.a. | 21136.0 | nM | PMID[467938] |
| NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 23109.3 | nM | PMID[467937] |
| NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 10000.0 | nM | PMID[467939] |
| NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 11885.6 | nM | PMID[467936] |
| NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 11220.2 | nM | PMID[467939] |
| NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | n.a. | 16360.1 | nM | PMID[467937] |
| NPT543 | Individual Protein | Pregnane X receptor | Homo sapiens | EC50 | = | 31600.0 | nM | PMID[467940] |
| NPT543 | Individual Protein | Pregnane X receptor | Homo sapiens | Efficacy | = | 138.7 | % | PMID[467940] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 53.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 27.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 5.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 51.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 2.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 46.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 20.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 110.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 29.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 60.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 36.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 45.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 14.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 32.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 40.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 85.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 17.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 34.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 133.0 | n.a. | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 49.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 21.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 1.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 3.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 50.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 106.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 33.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 57.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 31.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 13.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 25.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 42.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 86.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 22.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 44.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 132.0 | n.a. | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 63.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 7.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 107.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 75.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 15.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 11.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 24.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 84.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 28.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 136.0 | n.a. | PMID[467942] | |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 11.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 6.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 1.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 45.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 7.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 13.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 88.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 48.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 256.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 18.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 10.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 38.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 12.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 92.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 50.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 20.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 179.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 66.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 0.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 8.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 23.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 125.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 78.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 88.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 155.0 | n.a. | PMID[467942] | |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 9.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 0.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 24.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 17.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 90.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 67.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 233.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 4.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 8.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 5.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 22.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 2.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 91.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 95.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 71.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 195.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 71.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 16.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 35.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 150.0 | n.a. | PMID[467942] | |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 21.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 16.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 66.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 3.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 155.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 35.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 5.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 1.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 88.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 2.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 9.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 64.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 6.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 330.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 10.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 67.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 32.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 21.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 12.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 58.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 87.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 45.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 28.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 265.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 31.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 8.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 0.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 82.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 7.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 68.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 212.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 41.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 18.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 71.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 91.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 48.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 173.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 19.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 34.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 55.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 80.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 97.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 62.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 46.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 194.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 42.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 37.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 68.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 57.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 49.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 274.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 32.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 41.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 15.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 81.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 58.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 87.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 35.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 216.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 33.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 77.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 69.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 14.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 86.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 85.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 203.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 27.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 75.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 72.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 60.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 197.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 6.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 54.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 30.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 82.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 162.0 | n.a. | PMID[467942] | |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 39.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 51.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 293.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 31.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 30.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 82.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 100.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 231.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 351.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 26.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 59.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 98.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 40.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 89.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 227.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 70.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 210.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 28.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 248.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 70.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 10.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 83.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 18.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 177.0 | n.a. | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 69.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 59.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 47.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 77.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 9.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 80.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 186.0 | n.a. | PMID[467942] | |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 37.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 11.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 78.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 62.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 165.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 36.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 16.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 51.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 4.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 74.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 63.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 90.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 50.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 145.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 65.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 29.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 322.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 54.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 78.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 256.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 108.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 100.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 94.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 137.0 | n.a. | PMID[467942] | |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 43.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 86.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 56.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 153.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 19.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 13.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 83.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 182.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 64.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 90.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 123.0 | n.a. | PMID[467942] | |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 594.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 23.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 363.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 68.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 101.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 37.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 62.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 92.0 | n.a. | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 72.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 107.0 | n.a. | PMID[467942] | |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 61.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 93.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 96.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 207.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 70.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 26.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 152.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 89.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 131.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 81.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 15.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 73.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 14.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 100.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 85.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 17.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 78.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 25.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 27.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 75.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 194.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 49.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 3.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 91.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 91.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 12.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 91.0 | n.a. | PMID[467942] | |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 52.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 47.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 102.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 72.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 93.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 118.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 52.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 93.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 118.0 | n.a. | PMID[467942] | |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 76.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 89.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 76.0 | n.a. | PMID[467942] | |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 22.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 77.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 210.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 95.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 288.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 64.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 484.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 92.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 71.0 | n.a. | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 44.0 | % | PMID[467942] |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Multiplex | = | 383.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 80.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 229.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 84.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 98.0 | % | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 106.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Multiplex | = | 74.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 92.0 | % | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Multiplex | = | 74.0 | n.a. | PMID[467942] | |
| NPT2615 | Cell Line | HEK-293T | Homo sapiens | Cell Viability | = | 0.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Cell Viability | = | 0.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Cell Viability | = | 105160.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Cell Viability | = | 1.0 | n.a. | PMID[467942] | |
| NPT4909 | Cell Line | Fibroblasts | Cell Viability | = | 39.0 | n.a. | PMID[467942] | |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Cell Viability | = | 172.0 | n.a. | PMID[467942] |
| NPT1045 | Cell Line | U2OS | Homo sapiens | Cell Viability | = | 1.0 | n.a. | PMID[467942] |
| NPT4909 | Cell Line | Fibroblasts | Cell Viability | = | 0.0 | n.a. | PMID[467942] | |
| NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 21313.8 | nM | PubChem BioAssay data set |
| NPT153 | Individual Protein | Androgen Receptor | Homo sapiens | Potency | n.a. | 5955.7 | nM | PubChem BioAssay data set |
| NPT152 | Individual Protein | Nuclear factor erythroid 2-related factor 2 | Homo sapiens | Potency | n.a. | 2370.8 | nM | PubChem BioAssay data set |
| NPT1777 | Protein Family | Serotonin 2 (5-HT2) receptor | Rattus norvegicus | Ki | = | 2.0 | nM | PMID[467934] |
| NPT1777 | Protein Family | Serotonin 2 (5-HT2) receptor | Rattus norvegicus | Ratio | = | 2100.0 | n.a. | PMID[467934] |
| NPT2 | Others | Unspecified | Potency | = | 39810.7 | nM | PMID[467936] | |
| NPT698 | Individual Protein | Regulator of G-protein signaling 4 | Homo sapiens | Potency | n.a. | 843.7 | nM | PMID[467937] |
| NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 16944.1 | nM | PMID[467938] |
| NPT888 | Individual Protein | 78 kDa glucose-regulated protein | Homo sapiens | Potency | n.a. | 25118.9 | nM | PMID[467936] |
| NPT888 | Individual Protein | 78 kDa glucose-regulated protein | Homo sapiens | Potency | n.a. | 12589.3 | nM | PMID[467937] |
| NPT2 | Others | Unspecified | Potency | n.a. | 15848.9 | nM | PMID[467936] | |
| NPT2 | Others | Unspecified | Potency | n.a. | 22387.2 | nM | PMID[467937] | |
| NPT2 | Others | Unspecified | Potency | n.a. | 10000.0 | nM | PMID[467939] | |
| NPT2 | Others | Unspecified | Potency | n.a. | 50118.7 | nM | PMID[467939] | |
| NPT2 | Others | Unspecified | Potency | n.a. | 11220.2 | nM | PMID[467936] | |
| NPT2 | Others | Unspecified | Potency | n.a. | 14125.4 | nM | PMID[467937] | |
| NPT2 | Others | Unspecified | Potency | n.a. | 17782.8 | nM | PMID[467939] | |
| NPT2 | Others | Unspecified | Ac50 | n.a. | 12.19 | uM | PMID[467941] | |
| NPT2 | Others | Unspecified | AC50 | n.a. | 3162.3 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 2457.93 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 881.74 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 5332.76 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 8819.81 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | n.a. | 33330.0 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | Ac50 | n.a. | 3.162 | uM | PMID[467941] | |
| NPT2 | Others | Unspecified | Ac50 | n.a. | 19.31 | uM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 4607.81 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 241.58 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 5305.1 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | IC50 | = | 11821.0 | nM | PMID[467941] | |
| NPT2 | Others | Unspecified | Ac50 | n.a. | 6.853 | uM | PMID[467941] | |
| NPT2 | Others | Unspecified | Potency | n.a. | 5308 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 29847 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 7497.8 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 118.8 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 26832.5 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 8485.2 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 23708.3 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 13333.2 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 3349.1 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 16785.5 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 29849.3 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 3348.9 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 10682.2 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 10590.9 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 5955.3 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 11883.2 | nM | PubChem BioAssay data set | |
| NPT74 | Individual Protein | Proto-oncogene c-JUN | Homo sapiens | Potency | n.a. | 9520.5 | nM | PubChem BioAssay data set |
| NPT2 | Others | Unspecified | Potency | n.a. | 14960.1 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 23710.1 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 2131.4 | nM | PubChem BioAssay data set | |
| NPT2 | Others | Unspecified | Potency | n.a. | 21131.7 | nM | PubChem BioAssay data set |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Chemically structural similarity: I. Similar Active Natural Products in NPASSTop-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient 
● The left chart: Distribution of similarity level between NPC315257 and all remaining natural products in the NPASS database.
● The right table: Most similar natural products (Tc>=0.56 or Top200).
| Similarity Score | Similarity Level | Natural Product ID |
|---|---|---|
| 0.6879 | Remote Similarity | NPC315498 |
| 0.6879 | Remote Similarity | NPC230942 |
| 0.6871 | Remote Similarity | NPC212850 |
| 0.6871 | Remote Similarity | NPC83289 |
| 0.6871 | Remote Similarity | NPC189724 |
| 0.6824 | Remote Similarity | NPC264782 |
| 0.6807 | Remote Similarity | NPC247298 |
| 0.6774 | Remote Similarity | NPC315632 |
| 0.6747 | Remote Similarity | NPC260601 |
| 0.6742 | Remote Similarity | NPC85482 |
| 0.6726 | Remote Similarity | NPC245974 |
| 0.672 | Remote Similarity | NPC110741 |
| 0.6708 | Remote Similarity | NPC184437 |
| 0.6705 | Remote Similarity | NPC70172 |
| 0.6687 | Remote Similarity | NPC168750 |
| 0.6686 | Remote Similarity | NPC177404 |
| 0.6685 | Remote Similarity | NPC283152 |
| 0.6667 | Remote Similarity | NPC118776 |
| 0.6667 | Remote Similarity | NPC314113 |
| 0.6649 | Remote Similarity | NPC478049 |
| 0.6649 | Remote Similarity | NPC314948 |
| 0.6648 | Remote Similarity | NPC471648 |
| 0.6646 | Remote Similarity | NPC274732 |
| 0.6627 | Remote Similarity | NPC476462 |
| 0.6626 | Remote Similarity | NPC237227 |
| 0.6609 | Remote Similarity | NPC26850 |
| 0.6603 | Remote Similarity | NPC471315 |
| 0.6603 | Remote Similarity | NPC471314 |
| 0.6592 | Remote Similarity | NPC477888 |
| 0.6564 | Remote Similarity | NPC52801 |
| 0.6543 | Remote Similarity | NPC471953 |
| 0.6538 | Remote Similarity | NPC473432 |
| 0.6532 | Remote Similarity | NPC26872 |
| 0.6522 | Remote Similarity | NPC473987 |
| 0.6517 | Remote Similarity | NPC24954 |
| 0.6516 | Remote Similarity | NPC263835 |
| 0.651 | Remote Similarity | NPC95977 |
| 0.6503 | Remote Similarity | NPC297584 |
| 0.6486 | Remote Similarity | NPC219963 |
| 0.6474 | Remote Similarity | NPC28510 |
| 0.6474 | Remote Similarity | NPC274026 |
| 0.6465 | Remote Similarity | NPC472111 |
| 0.6457 | Remote Similarity | NPC10730 |
| 0.6457 | Remote Similarity | NPC10875 |
| 0.6455 | Remote Similarity | NPC217294 |
| 0.6452 | Remote Similarity | NPC469831 |
| 0.6452 | Remote Similarity | NPC98197 |
| 0.6452 | Remote Similarity | NPC256369 |
| 0.645 | Remote Similarity | NPC469589 |
| 0.6448 | Remote Similarity | NPC288943 |
| 0.6446 | Remote Similarity | NPC476475 |
| 0.6425 | Remote Similarity | NPC254700 |
| 0.6421 | Remote Similarity | NPC174629 |
| 0.6417 | Remote Similarity | NPC469829 |
| 0.6414 | Remote Similarity | NPC47059 |
| 0.6414 | Remote Similarity | NPC118832 |
| 0.6414 | Remote Similarity | NPC165349 |
| 0.6414 | Remote Similarity | NPC329708 |
| 0.6414 | Remote Similarity | NPC274291 |
| 0.6414 | Remote Similarity | NPC264166 |
| 0.641 | Remote Similarity | NPC53596 |
| 0.641 | Remote Similarity | NPC471308 |
| 0.641 | Remote Similarity | NPC289330 |
| 0.641 | Remote Similarity | NPC160120 |
| 0.641 | Remote Similarity | NPC17388 |
| 0.6406 | Remote Similarity | NPC203972 |
| 0.6404 | Remote Similarity | NPC59028 |
| 0.6404 | Remote Similarity | NPC92191 |
| 0.6402 | Remote Similarity | NPC66083 |
| 0.6402 | Remote Similarity | NPC469830 |
| 0.64 | Remote Similarity | NPC133011 |
| 0.64 | Remote Similarity | NPC82285 |
| 0.6398 | Remote Similarity | NPC161887 |
| 0.6398 | Remote Similarity | NPC266551 |
| 0.6396 | Remote Similarity | NPC311357 |
| 0.638 | Remote Similarity | NPC476685 |
| 0.638 | Remote Similarity | NPC476687 |
| 0.638 | Remote Similarity | NPC476689 |
| 0.6379 | Remote Similarity | NPC219383 |
| 0.6379 | Remote Similarity | NPC13397 |
| 0.6378 | Remote Similarity | NPC316161 |
| 0.6374 | Remote Similarity | NPC130926 |
| 0.6374 | Remote Similarity | NPC9373 |
| 0.6373 | Remote Similarity | NPC198401 |
| 0.6368 | Remote Similarity | NPC477186 |
| 0.6354 | Remote Similarity | NPC204970 |
| 0.6349 | Remote Similarity | NPC276674 |
| 0.6349 | Remote Similarity | NPC33902 |
| 0.6348 | Remote Similarity | NPC306366 |
| 0.6348 | Remote Similarity | NPC231862 |
| 0.6348 | Remote Similarity | NPC235628 |
| 0.6348 | Remote Similarity | NPC285635 |
| 0.6348 | Remote Similarity | NPC93653 |
| 0.6346 | Remote Similarity | NPC43275 |
| 0.6341 | Remote Similarity | NPC208022 |
| 0.6335 | Remote Similarity | NPC473569 |
| 0.6333 | Remote Similarity | NPC471178 |
| 0.6333 | Remote Similarity | NPC204179 |
| 0.6324 | Remote Similarity | NPC471080 |
| 0.6324 | Remote Similarity | NPC469592 |
| 0.6324 | Remote Similarity | NPC478074 |
| 0.6324 | Remote Similarity | NPC220560 |
| 0.6324 | Remote Similarity | NPC285941 |
| 0.6323 | Remote Similarity | NPC323948 |
| 0.6321 | Remote Similarity | NPC79293 |
| 0.6321 | Remote Similarity | NPC279401 |
| 0.6318 | Remote Similarity | NPC475910 |
| 0.6313 | Remote Similarity | NPC124542 |
| 0.6313 | Remote Similarity | NPC471177 |
| 0.6313 | Remote Similarity | NPC59779 |
| 0.6313 | Remote Similarity | NPC57105 |
| 0.631 | Remote Similarity | NPC204156 |
| 0.6306 | Remote Similarity | NPC41801 |
| 0.6304 | Remote Similarity | NPC312872 |
| 0.6302 | Remote Similarity | NPC470483 |
| 0.6301 | Remote Similarity | NPC476151 |
| 0.6298 | Remote Similarity | NPC314861 |
| 0.6292 | Remote Similarity | NPC84508 |
| 0.6286 | Remote Similarity | NPC47672 |
| 0.6284 | Remote Similarity | NPC14651 |
| 0.6284 | Remote Similarity | NPC121658 |
| 0.6281 | Remote Similarity | NPC473460 |
| 0.628 | Remote Similarity | NPC313466 |
| 0.6279 | Remote Similarity | NPC185838 |
| 0.6278 | Remote Similarity | NPC118511 |
| 0.6273 | Remote Similarity | NPC29477 |
| 0.6273 | Remote Similarity | NPC476249 |
| 0.6271 | Remote Similarity | NPC233926 |
| 0.6271 | Remote Similarity | NPC112766 |
| 0.627 | Remote Similarity | NPC290069 |
| 0.6269 | Remote Similarity | NPC478075 |
| 0.6264 | Remote Similarity | NPC1527 |
| 0.6258 | Remote Similarity | NPC471321 |
| 0.6258 | Remote Similarity | NPC471306 |
| 0.6258 | Remote Similarity | NPC226662 |
| 0.6257 | Remote Similarity | NPC222592 |
| 0.6257 | Remote Similarity | NPC168486 |
| 0.6257 | Remote Similarity | NPC70092 |
| 0.6256 | Remote Similarity | NPC473053 |
| 0.625 | Remote Similarity | NPC470484 |
| 0.625 | Remote Similarity | NPC14339 |
| 0.6243 | Remote Similarity | NPC299582 |
| 0.6242 | Remote Similarity | NPC97870 |
| 0.6242 | Remote Similarity | NPC247018 |
| 0.6242 | Remote Similarity | NPC307123 |
| 0.6237 | Remote Similarity | NPC470485 |
| 0.6237 | Remote Similarity | NPC289786 |
| 0.6236 | Remote Similarity | NPC469428 |
| 0.6236 | Remote Similarity | NPC70549 |
| 0.6231 | Remote Similarity | NPC474077 |
| 0.623 | Remote Similarity | NPC232872 |
| 0.623 | Remote Similarity | NPC476518 |
| 0.6229 | Remote Similarity | NPC258222 |
| 0.6229 | Remote Similarity | NPC103379 |
| 0.6229 | Remote Similarity | NPC477565 |
| 0.6224 | Remote Similarity | NPC472191 |
| 0.6223 | Remote Similarity | NPC270301 |
| 0.6223 | Remote Similarity | NPC288305 |
| 0.6223 | Remote Similarity | NPC477891 |
| 0.6222 | Remote Similarity | NPC133470 |
| 0.6222 | Remote Similarity | NPC476231 |
| 0.6222 | Remote Similarity | NPC191863 |
| 0.6222 | Remote Similarity | NPC289776 |
| 0.6219 | Remote Similarity | NPC471736 |
| 0.6212 | Remote Similarity | NPC329747 |
| 0.6211 | Remote Similarity | NPC62101 |
| 0.6211 | Remote Similarity | NPC95733 |
| 0.6211 | Remote Similarity | NPC42591 |
| 0.6207 | Remote Similarity | NPC191376 |
| 0.6207 | Remote Similarity | NPC179825 |
| 0.6207 | Remote Similarity | NPC321505 |
| 0.6203 | Remote Similarity | NPC472168 |
| 0.6203 | Remote Similarity | NPC321133 |
| 0.6202 | Remote Similarity | NPC469594 |
| 0.6201 | Remote Similarity | NPC301163 |
| 0.62 | Remote Similarity | NPC76327 |
| 0.6198 | Remote Similarity | NPC320088 |
| 0.6196 | Remote Similarity | NPC172403 |
| 0.6196 | Remote Similarity | NPC258773 |
| 0.6194 | Remote Similarity | NPC303370 |
| 0.6188 | Remote Similarity | NPC198160 |
| 0.6186 | Remote Similarity | NPC473004 |
| 0.6185 | Remote Similarity | NPC473769 |
| 0.6181 | Remote Similarity | NPC214368 |
| 0.6178 | Remote Similarity | NPC262725 |
| 0.6178 | Remote Similarity | NPC204385 |
| 0.6176 | Remote Similarity | NPC314682 |
| 0.6173 | Remote Similarity | NPC250476 |
| 0.6171 | Remote Similarity | NPC246587 |
| 0.6171 | Remote Similarity | NPC135538 |
| 0.6171 | Remote Similarity | NPC147390 |
| 0.6171 | Remote Similarity | NPC476571 |
| 0.6171 | Remote Similarity | NPC428 |
| 0.6171 | Remote Similarity | NPC24233 |
| 0.617 | Remote Similarity | NPC287588 |
| 0.6169 | Remote Similarity | NPC473422 |
| 0.6168 | Remote Similarity | NPC29650 |
| 0.6166 | Remote Similarity | NPC474904 |
| 0.6166 | Remote Similarity | NPC474059 |
| 0.6163 | Remote Similarity | NPC470403 |
Chemically structural similarity: II. Similar Clinical/Approved DrugsSimilarity level is defined by Tanimoto coefficient (Tc) between two molecules.
● The left chart: Distribution of similarity level between NPC315257 and all drugs/candidates.
● The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
| Similarity Score | Similarity Level | Drug ID | Developmental Stage |
|---|---|---|---|
| 0.7901 | Intermediate Similarity | NPD6060 | Clinical (unspecified phase) |
| 0.7692 | Intermediate Similarity | NPD5078 | Clinical (unspecified phase) |
| 0.7669 | Intermediate Similarity | NPD4201 | Clinical (unspecified phase) |
| 0.7561 | Intermediate Similarity | NPD4255 | Phase 1 |
| 0.7546 | Intermediate Similarity | NPD6357 | Discontinued |
| 0.7543 | Intermediate Similarity | NPD7877 | Suspended |
| 0.7456 | Intermediate Similarity | NPD4943 | Phase 2 |
| 0.7456 | Intermediate Similarity | NPD4944 | Phase 2 |
| 0.7421 | Intermediate Similarity | NPD44 | Approved |
| 0.7421 | Intermediate Similarity | NPD6364 | Approved |
| 0.7412 | Intermediate Similarity | NPD6379 | Discontinued |
| 0.7399 | Intermediate Similarity | NPD4020 | Clinical (unspecified phase) |
| 0.7358 | Intermediate Similarity | NPD5719 | Approved |
| 0.7345 | Intermediate Similarity | NPD6338 | Approved |
| 0.7345 | Intermediate Similarity | NPD6337 | Approved |
| 0.7341 | Intermediate Similarity | NPD7032 | Approved |
| 0.7321 | Intermediate Similarity | NPD6063 | Approved |
| 0.7283 | Intermediate Similarity | NPD6607 | Clinical (unspecified phase) |
| 0.7273 | Intermediate Similarity | NPD5267 | Discontinued |
| 0.7273 | Intermediate Similarity | NPD1678 | Clinical (unspecified phase) |
| 0.7267 | Intermediate Similarity | NPD5847 | Phase 1 |
| 0.7262 | Intermediate Similarity | NPD6738 | Phase 2 |
| 0.7262 | Intermediate Similarity | NPD6737 | Phase 2 |
| 0.725 | Intermediate Similarity | NPD4597 | Approved |
| 0.725 | Intermediate Similarity | NPD4598 | Approved |
| 0.7244 | Intermediate Similarity | NPD7200 | Approved |
| 0.7241 | Intermediate Similarity | NPD5938 | Phase 3 |
| 0.7233 | Intermediate Similarity | NPD1422 | Approved |
| 0.7232 | Intermediate Similarity | NPD7149 | Clinical (unspecified phase) |
| 0.7219 | Intermediate Similarity | NPD6524 | Clinical (unspecified phase) |
| 0.7216 | Intermediate Similarity | NPD795 | Clinical (unspecified phase) |
| 0.7212 | Intermediate Similarity | NPD8330 | Clinical (unspecified phase) |
| 0.7209 | Intermediate Similarity | NPD4986 | Clinical (unspecified phase) |
| 0.7205 | Intermediate Similarity | NPD2459 | Approved |
| 0.7205 | Intermediate Similarity | NPD2458 | Approved |
| 0.7205 | Intermediate Similarity | NPD2460 | Phase 3 |
| 0.7204 | Intermediate Similarity | NPD5547 | Clinical (unspecified phase) |
| 0.7197 | Intermediate Similarity | NPD654 | Phase 3 |
| 0.7174 | Intermediate Similarity | NPD4523 | Approved |
| 0.7143 | Intermediate Similarity | NPD2845 | Phase 2 |
| 0.7143 | Intermediate Similarity | NPD2843 | Phase 2 |
| 0.7143 | Intermediate Similarity | NPD6136 | Phase 2 |
| 0.7143 | Intermediate Similarity | NPD6880 | Phase 3 |
| 0.7134 | Intermediate Similarity | NPD1393 | Approved |
| 0.711 | Intermediate Similarity | NPD3984 | Clinical (unspecified phase) |
| 0.711 | Intermediate Similarity | NPD3983 | Phase 3 |
| 0.7107 | Intermediate Similarity | NPD696 | Discontinued |
| 0.7102 | Intermediate Similarity | NPD4498 | Clinical (unspecified phase) |
| 0.7101 | Intermediate Similarity | NPD1861 | Discovery |
| 0.7097 | Intermediate Similarity | NPD5652 | Approved |
| 0.7097 | Intermediate Similarity | NPD5650 | Approved |
| 0.7097 | Intermediate Similarity | NPD5651 | Approved |
| 0.7095 | Intermediate Similarity | NPD254 | Approved |
| 0.7091 | Intermediate Similarity | NPD2874 | Phase 2 |
| 0.7072 | Intermediate Similarity | NPD6339 | Approved |
| 0.7072 | Intermediate Similarity | NPD6340 | Approved |
| 0.7065 | Intermediate Similarity | NPD5587 | Approved |
| 0.7065 | Intermediate Similarity | NPD6569 | Phase 2 |
| 0.7059 | Intermediate Similarity | NPD6877 | Discontinued |
| 0.7029 | Intermediate Similarity | NPD4083 | Discontinued |
| 0.7027 | Intermediate Similarity | NPD7262 | Phase 1 |
| 0.7024 | Intermediate Similarity | NPD789 | Phase 2 |
| 0.7006 | Intermediate Similarity | NPD5132 | Clinical (unspecified phase) |
| 0.7006 | Intermediate Similarity | NPD3627 | Approved |
| 0.7005 | Intermediate Similarity | NPD2952 | Discontinued |
| 0.7 | Intermediate Similarity | NPD6461 | Clinical (unspecified phase) |
| 0.7 | Intermediate Similarity | NPD2594 | Approved |
| 0.7 | Intermediate Similarity | NPD2595 | Approved |
| 0.7 | Intermediate Similarity | NPD1769 | Discontinued |
| 0.6995 | Remote Similarity | NPD6608 | Clinical (unspecified phase) |
| 0.6983 | Remote Similarity | NPD6211 | Clinical (unspecified phase) |
| 0.6982 | Remote Similarity | NPD3679 | Phase 2 |
| 0.6957 | Remote Similarity | NPD3693 | Clinical (unspecified phase) |
| 0.6957 | Remote Similarity | NPD6380 | Phase 1 |
| 0.6957 | Remote Similarity | NPD4081 | Clinical (unspecified phase) |
| 0.6954 | Remote Similarity | NPD6767 | Clinical (unspecified phase) |
| 0.6947 | Remote Similarity | NPD6604 | Discontinued |
| 0.6944 | Remote Similarity | NPD4203 | Approved |
| 0.6944 | Remote Similarity | NPD4204 | Approved |
| 0.6941 | Remote Similarity | NPD4205 | Phase 3 |
| 0.6932 | Remote Similarity | NPD5680 | Clinical (unspecified phase) |
| 0.6932 | Remote Similarity | NPD2216 | Approved |
| 0.6932 | Remote Similarity | NPD2215 | Approved |
| 0.6931 | Remote Similarity | NPD6757 | Phase 3 |
| 0.6923 | Remote Similarity | NPD4993 | Discontinued |
| 0.6923 | Remote Similarity | NPD5811 | Approved |
| 0.6915 | Remote Similarity | NPD4673 | Phase 2 |
| 0.6914 | Remote Similarity | NPD3156 | Discontinued |
| 0.6909 | Remote Similarity | NPD2945 | Clinical (unspecified phase) |
| 0.6902 | Remote Similarity | NPD4021 | Phase 2 |
| 0.6897 | Remote Similarity | NPD4796 | Discontinued |
| 0.6895 | Remote Similarity | NPD4396 | Clinical (unspecified phase) |
| 0.6885 | Remote Similarity | NPD3316 | Clinical (unspecified phase) |
| 0.6882 | Remote Similarity | NPD4324 | Phase 2 |
| 0.6882 | Remote Similarity | NPD4325 | Phase 2 |
| 0.6879 | Remote Similarity | NPD19 | Approved |
| 0.6879 | Remote Similarity | NPD1743 | Approved |
| 0.6879 | Remote Similarity | NPD1742 | Approved |
| 0.6872 | Remote Similarity | NPD5334 | Clinical (unspecified phase) |
| 0.6871 | Remote Similarity | NPD3656 | Approved |
| 0.6868 | Remote Similarity | NPD5083 | Clinical (unspecified phase) |
| 0.6864 | Remote Similarity | NPD3563 | Approved |
| 0.6864 | Remote Similarity | NPD3564 | Approved |
| 0.6864 | Remote Similarity | NPD3562 | Approved |
| 0.686 | Remote Similarity | NPD5294 | Clinical (unspecified phase) |
| 0.6859 | Remote Similarity | NPD6592 | Clinical (unspecified phase) |
| 0.6857 | Remote Similarity | NPD2162 | Clinical (unspecified phase) |
| 0.6852 | Remote Similarity | NPD822 | Approved |
| 0.6851 | Remote Similarity | NPD3037 | Phase 1 |
| 0.6848 | Remote Similarity | NPD6748 | Discontinued |
| 0.6834 | Remote Similarity | NPD5101 | Discontinued |
| 0.6828 | Remote Similarity | NPD4148 | Approved |
| 0.6828 | Remote Similarity | NPD6656 | Clinical (unspecified phase) |
| 0.6826 | Remote Similarity | NPD2752 | Clinical (unspecified phase) |
| 0.6826 | Remote Similarity | NPD2114 | Discontinued |
| 0.6825 | Remote Similarity | NPD5515 | Phase 2 |
| 0.6825 | Remote Similarity | NPD6034 | Phase 2 |
| 0.6824 | Remote Similarity | NPD5639 | Clinical (unspecified phase) |
| 0.6821 | Remote Similarity | NPD3560 | Approved |
| 0.6821 | Remote Similarity | NPD3558 | Approved |
| 0.6821 | Remote Similarity | NPD3556 | Approved |
| 0.6821 | Remote Similarity | NPD3557 | Approved |
| 0.6821 | Remote Similarity | NPD3559 | Clinical (unspecified phase) |
| 0.6809 | Remote Similarity | NPD3395 | Approved |
| 0.6809 | Remote Similarity | NPD3396 | Approved |
| 0.6809 | Remote Similarity | NPD6861 | Clinical (unspecified phase) |
| 0.6807 | Remote Similarity | NPD5595 | Clinical (unspecified phase) |
| 0.6802 | Remote Similarity | NPD6453 | Phase 1 |
| 0.68 | Remote Similarity | NPD5059 | Clinical (unspecified phase) |
| 0.6798 | Remote Similarity | NPD6365 | Clinical (unspecified phase) |
| 0.6798 | Remote Similarity | NPD5858 | Discontinued |
| 0.6796 | Remote Similarity | NPD6654 | Clinical (unspecified phase) |
| 0.6793 | Remote Similarity | NPD6638 | Approved |
| 0.6791 | Remote Similarity | NPD4372 | Phase 1 |
| 0.6786 | Remote Similarity | NPD681 | Clinical (unspecified phase) |
| 0.6784 | Remote Similarity | NPD3296 | Phase 1 |
| 0.6778 | Remote Similarity | NPD5600 | Discontinued |
| 0.6771 | Remote Similarity | NPD7566 | Clinical (unspecified phase) |
| 0.6769 | Remote Similarity | NPD2885 | Approved |
| 0.6769 | Remote Similarity | NPD7222 | Phase 2 |
| 0.6769 | Remote Similarity | NPD2886 | Approved |
| 0.6763 | Remote Similarity | NPD2842 | Clinical (unspecified phase) |
| 0.6757 | Remote Similarity | NPD4515 | Suspended |
| 0.6755 | Remote Similarity | NPD5150 | Phase 2 |
| 0.6755 | Remote Similarity | NPD6046 | Clinical (unspecified phase) |
| 0.6754 | Remote Similarity | NPD6874 | Approved |
| 0.6753 | Remote Similarity | NPD5628 | Clinical (unspecified phase) |
| 0.6752 | Remote Similarity | NPD2990 | Approved |
| 0.6752 | Remote Similarity | NPD2987 | Approved |
| 0.675 | Remote Similarity | NPD7477 | Discontinued |
| 0.6744 | Remote Similarity | NPD3236 | Phase 3 |
| 0.6744 | Remote Similarity | NPD3237 | Clinical (unspecified phase) |
| 0.674 | Remote Similarity | NPD5900 | Clinical (unspecified phase) |
| 0.674 | Remote Similarity | NPD2825 | Approved |
| 0.674 | Remote Similarity | NPD2826 | Approved |
| 0.674 | Remote Similarity | NPD2827 | Approved |
| 0.6735 | Remote Similarity | NPD5863 | Clinical (unspecified phase) |
| 0.6734 | Remote Similarity | NPD6177 | Clinical (unspecified phase) |
| 0.6734 | Remote Similarity | NPD5944 | Phase 1 |
| 0.6734 | Remote Similarity | NPD5945 | Phase 1 |
| 0.6727 | Remote Similarity | NPD4149 | Clinical (unspecified phase) |
| 0.6725 | Remote Similarity | NPD6523 | Clinical (unspecified phase) |
| 0.6723 | Remote Similarity | NPD3858 | Discontinued |
| 0.6721 | Remote Similarity | NPD4012 | Approved |
| 0.672 | Remote Similarity | NPD7326 | Phase 3 |
| 0.672 | Remote Similarity | NPD4681 | Clinical (unspecified phase) |
| 0.6719 | Remote Similarity | NPD6810 | Clinical (unspecified phase) |
| 0.6719 | Remote Similarity | NPD6519 | Phase 2 |
| 0.6717 | Remote Similarity | NPD6220 | Phase 3 |
| 0.6707 | Remote Similarity | NPD6606 | Clinical (unspecified phase) |
| 0.6703 | Remote Similarity | NPD4920 | Clinical (unspecified phase) |
| 0.6703 | Remote Similarity | NPD4921 | Phase 3 |
| 0.6703 | Remote Similarity | NPD4919 | Phase 3 |
| 0.6701 | Remote Similarity | NPD3804 | Discontinued |
| 0.67 | Remote Similarity | NPD7538 | Clinical (unspecified phase) |
| 0.6698 | Remote Similarity | NPD6605 | Phase 3 |
| 0.6686 | Remote Similarity | NPD4871 | Phase 2 |
| 0.6685 | Remote Similarity | NPD5521 | Clinical (unspecified phase) |
| 0.6685 | Remote Similarity | NPD3504 | Approved |
| 0.6685 | Remote Similarity | NPD3503 | Approved |
| 0.6685 | Remote Similarity | NPD4071 | Approved |
| 0.6685 | Remote Similarity | NPD5670 | Approved |
| 0.6685 | Remote Similarity | NPD3793 | Phase 3 |
| 0.6685 | Remote Similarity | NPD4072 | Approved |
| 0.6684 | Remote Similarity | NPD5582 | Discontinued |
| 0.6684 | Remote Similarity | NPD2410 | Phase 2 |
| 0.6683 | Remote Similarity | NPD7178 | Clinical (unspecified phase) |
| 0.6667 | Remote Similarity | NPD7752 | Approved |
| 0.6667 | Remote Similarity | NPD7030 | Discontinued |
| 0.6667 | Remote Similarity | NPD7753 | Approved |
| 0.6667 | Remote Similarity | NPD5645 | Phase 3 |
| 0.6667 | Remote Similarity | NPD1034 | Phase 3 |
| 0.6667 | Remote Similarity | NPD6382 | Discontinued |
| 0.6667 | Remote Similarity | NPD6393 | Clinical (unspecified phase) |
| 0.6667 | Remote Similarity | NPD5102 | Clinical (unspecified phase) |
| 0.6667 | Remote Similarity | NPD1033 | Clinical (unspecified phase) |
| 0.6667 | Remote Similarity | NPD5602 | Clinical (unspecified phase) |
| 0.6649 | Remote Similarity | NPD6769 | Clinical (unspecified phase) |
| 0.6649 | Remote Similarity | NPD7491 | Clinical (unspecified phase) |
| 0.6647 | Remote Similarity | NPD2469 | Approved |
Bioactivity similarity: Similar Natural Products in NPASSBioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.
